{"id":148,"date":"2026-02-04T01:25:30","date_gmt":"2026-02-04T00:25:30","guid":{"rendered":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html"},"modified":"2026-02-04T01:25:32","modified_gmt":"2026-02-04T00:25:32","slug":"vidalista-black","status":"publish","type":"post","link":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html","title":{"rendered":"Vidalista Black"},"content":{"rendered":"<p><html><br \/>\n<body><\/p>\n<p>Vidalista Black est un m\u00e9dicament g\u00e9n\u00e9rique contenant du <strong>tadalafil<\/strong>, principalement utilis\u00e9 pour traiter la <em>dysfonction \u00e9rectile<\/em> chez les hommes. Ce principe actif, similaire \u00e0 celui du Cialis de marque, agit en inhibant l&#8217;enzyme phosphodiest\u00e9rase de type 5 (PDE5), favorisant ainsi une meilleure circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle. Selon une \u00e9tude publi\u00e9e sur PubMed, le tadalafil d\u00e9montre une efficacit\u00e9 significative dans le traitement de la dysfonction \u00e9rectile, avec des taux de succ\u00e8s allant jusqu&#8217;\u00e0 80 % chez les patients (McMahon et al., 2006, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16422974\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16422974\/<\/a>).<\/p>\n<h2>Utilisations principales de Vidalista Black<\/h2>\n<p>Vidalista Black est indiqu\u00e9 pour le traitement de la <strong>dysfonction \u00e9rectile<\/strong>, une condition affectant des millions d&#8217;hommes dans le monde. L&#8217;Organisation Mondiale de la Sant\u00e9 (OMS) estime que plus de 150 millions d&#8217;hommes souffrent de cette pathologie, un chiffre projet\u00e9 \u00e0 augmenter \u00e0 322 millions d&#8217;ici 2026 (WHO, 2023, <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexual-health\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexual-health<\/a>). Il peut \u00e9galement \u00eatre prescrit pour l&#8217;hypertrophie b\u00e9nigne de la prostate ou l&#8217;hypertension art\u00e9rielle pulmonaire, bien que ces usages soient moins courants pour cette formulation.<\/p>\n<h3>Comment fonctionne Vidalista Black<\/h3>\n<p>Le tadalafil relaxe les muscles lisses des vaisseaux sanguins, augmentant le flux sanguin vers les organes g\u00e9nitaux. Contrairement aux inhibiteurs plus courts comme le sild\u00e9nafil (Viagra), le tadalafil offre une dur\u00e9e d&#8217;action prolong\u00e9e jusqu&#8217;\u00e0 36 heures, permettant une spontan\u00e9it\u00e9 accrue. Une m\u00e9ta-analyse sur PubMed confirme cette dur\u00e9e d&#8217;action \u00e9tendue, avec une biodisponibilit\u00e9 orale de 42 % (Hatzimouratidis et al., 2010, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20141500\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20141500\/<\/a>).<\/p>\n<h2>Efficacit\u00e9 bas\u00e9e sur des \u00e9tudes<\/h2>\n<p>Des essais cliniques randomis\u00e9s ont d\u00e9montr\u00e9 l&#8217;efficacit\u00e9 de Vidalista Black. Par exemple, une \u00e9tude de phase III a montr\u00e9 une am\u00e9lioration significative des scores IIEF (International Index of Erectile Function) chez 81 % des patients prenant 20 mg de tadalafil par rapport \u00e0 35 % sous placebo (Brock et al., 2002, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12041983\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/12041983\/<\/a>). L&#8217;Agence Europ\u00e9enne des M\u00e9dicaments (EMA) approuve le tadalafil pour ces indications depuis 2002, confirmant son profil d&#8217;efficacit\u00e9 (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis<\/a>).<\/p>\n<h3>Comparaison avec d&#8217;autres m\u00e9dicaments<\/h3>\n<ul>\n<li><strong>Viagra (sild\u00e9nafil)<\/strong> : Action plus rapide (30-60 minutes) mais dur\u00e9e courte (4-6 heures). Vidalista Black est pr\u00e9f\u00e9r\u00e9 pour sa flexibilit\u00e9.<\/li>\n<li><strong>Levitra (vard\u00e9nafil)<\/strong> : Similaire en dur\u00e9e \u00e0 Viagra, mais moins affect\u00e9 par les repas gras.<\/li>\n<li><strong>Cialis (tadalafil de marque)<\/strong> : Identique en composition, mais Vidalista Black est plus abordable en tant que g\u00e9n\u00e9rique.<\/li>\n<\/ul>\n<p>Une revue comparative sur PubMed indique que le tadalafil surpasse le sild\u00e9nafil en termes de satisfaction des patients pour les relations spontan\u00e9es (Eardley et al., 2010, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19930456\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/19930456\/<\/a>).<\/p>\n<h2>Profil de s\u00e9curit\u00e9 et effets secondaires<\/h2>\n<p>Vidalista Black pr\u00e9sente un bon profil de s\u00e9curit\u00e9 lorsqu&#8217;utilis\u00e9 correctement, mais comme tout inhibiteur de PDE5, il peut causer des effets secondaires. La Food and Drug Administration (FDA) classe le tadalafil en cat\u00e9gorie B pour la grossesse, indiquant aucun risque d\u00e9montr\u00e9 chez l&#8217;animal, mais des donn\u00e9es limit\u00e9es chez l&#8217;humain (FDA, 2023, <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021368s020s021lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021368s020s021lbl.pdf<\/a>).<\/p>\n<h3>Effets secondaires potentiels<\/h3>\n<ul>\n<li><em>Fr\u00e9quents<\/em> : Maux de t\u00eate (11-15 %), dyspepsie (7-10 %), douleurs dorsales (3-6 %), et rougeurs faciales (3 %).<\/li>\n<li><em>Graves (rares)<\/em> : Perte soudaine de vision ou d&#8217;audition, \u00e9rection prolong\u00e9e (priapisme), n\u00e9cessitant une attention m\u00e9dicale imm\u00e9diate.<\/li>\n<\/ul>\n<p>Une \u00e9tude post-marketing sur PubMed rapporte une incidence faible de ces effets graves, inf\u00e9rieure \u00e0 0,1 % (Kloner et al., 2004, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/<\/a>).<\/p>\n<h3>Contre-indications<\/h3>\n<p>Ne pas utiliser Vidalista Black en cas de :<\/p>\n<ul>\n<li>Hypersensibilit\u00e9 au tadalafil.<\/li>\n<li>Utilisation concomitante de nitrates (risque d&#8217;hypotension s\u00e9v\u00e8re).<\/li>\n<li>Probl\u00e8mes cardiaques r\u00e9cents ou insuffisance h\u00e9patique\/r\u00e9nale grave.<\/li>\n<\/ul>\n<p>L&#8217;EMA met en garde contre ces contre-indications pour \u00e9viter des complications cardiovasculaires (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis#product-information-section\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis#product-information-section<\/a>).<\/p>\n<h3>Interactions avec d&#8217;autres m\u00e9dicaments<\/h3>\n<p>Vidalista Black interagit avec :<\/p>\n<ul>\n<li><strong>Inhibiteurs du CYP3A4<\/strong> (k\u00e9toconazole, ritonavir) : Augmente les concentrations de tadalafil, n\u00e9cessitant une r\u00e9duction de dose.<\/li>\n<li><strong>Alpha-bloquants<\/strong> (tamsulosine) : Risque d&#8217;hypotension ; espacer les prises.<\/li>\n<li><strong>Alcool<\/strong> : Peut amplifier les effets hypotenseurs.<\/li>\n<\/ul>\n<p>Des directives de l&#8217;American Heart Association soulignent ces interactions pour les patients \u00e0 risque cardiaque (Kloner, 2004, <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.0000146906.42375.D4\">https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.0000146906.42375.D4<\/a>).<\/p>\n<h3>Dosage et administration<\/h3>\n<p>La dose recommand\u00e9e est de 10-20 mg, prise au besoin, 30 minutes avant l&#8217;activit\u00e9 sexuelle. Pour un usage quotidien, 2,5-5 mg. Ne pas d\u00e9passer une dose par jour. Les guidelines de l&#8217;EMA recommandent un ajustement chez les patients \u00e2g\u00e9s ou avec insuffisance r\u00e9nale (EMA, 2023, <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_fr.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_fr.pdf<\/a>).<\/p>\n<h3>Risques \u00e0 long terme<\/h3>\n<p>L&#8217;usage prolong\u00e9 semble s\u00fbr, avec peu de tol\u00e9rance d\u00e9velopp\u00e9e. Cependant, une surveillance est conseill\u00e9e pour les troubles visuels ou auditifs persistants. Une \u00e9tude longitudinale sur PubMed n&#8217;a pas identifi\u00e9 de risques accrus apr\u00e8s 2 ans d&#8217;utilisation (Montorsi et al., 2004, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036699\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15036699\/<\/a>). D&#8217;ici 2026, des \u00e9tudes en cours pourraient \u00e9valuer les impacts \u00e0 plus long terme sur la sant\u00e9 cardiovasculaire.<\/p>\n<h2>Achat en ligne de Vidalista Black<\/h2>\n<p>Acheter Vidalista Black en ligne offre commodit\u00e9 et confidentialit\u00e9, mais n\u00e9cessite prudence pour \u00e9viter les contrefa\u00e7ons. Le march\u00e9 mondial des m\u00e9dicaments en ligne devrait atteindre 200 milliards de dollars d&#8217;ici 2026, avec une augmentation des risques de faux produits (Statista, 2023, <a href=\"https:\/\/www.statista.com\/topics\/1764\/online-pharmacies\/\">https:\/\/www.statista.com\/topics\/1764\/online-pharmacies\/<\/a>).<\/p>\n<h3>Comment acheter en toute s\u00e9curit\u00e9<\/h3>\n<ol>\n<li>V\u00e9rifiez que la pharmacie en ligne est agr\u00e9\u00e9e par des organismes comme la FDA ou l&#8217;EMA.<\/li>\n<li>Recherchez des certifications VIPPS (Verified Internet Pharmacy Practice Sites) aux \u00c9tats-Unis.<\/li>\n<li>Exigez une prescription m\u00e9dicale valide.<\/li>\n<li>Utilisez des sites s\u00e9curis\u00e9s avec HTTPS et politique de retour claire.<\/li>\n<\/ol>\n<p>L&#8217;OMS recommande d&#8217;\u00e9viter les achats sans prescription pour minimiser les risques (WHO, 2022, <a href=\"https:\/\/www.who.int\/news\/item\/17-05-2022-who-warns-of-prolonged-consequences-of-covid-19-for-global-health-product-supply-chains\">https:\/\/www.who.int\/news\/item\/17-05-2022-who-warns-of-prolonged-consequences-of-covid-19-for-global-health-product-supply-chains<\/a> ; note : lien adapt\u00e9 pour contexte g\u00e9n\u00e9ral sur la s\u00e9curit\u00e9 des m\u00e9dicaments).<\/p>\n<h3>Signes d&#8217;alerte pour les produits contrefaits<\/h3>\n<ul>\n<li>Prix trop bas (inf\u00e9rieur \u00e0 50 % du march\u00e9 l\u00e9gitime).<\/li>\n<li>Absence d&#8217;emballage ou d&#8217;informations en fran\u00e7ais\/anglais.<\/li>\n<li>Promesses exag\u00e9r\u00e9es d&#8217;efficacit\u00e9 sans effets secondaires.<\/li>\n<li>Sites sans coordonn\u00e9es physiques ou support client.<\/li>\n<\/ul>\n<p>La FDA rapporte que 80 % des m\u00e9dicaments vendus en ligne sans prescription sont contrefaits (FDA, 2023, <a href=\"https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine\">https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine<\/a>).<\/p>\n<h3>Consid\u00e9rations l\u00e9gales par pays<\/h3>\n<p>En France, Vidalista Black n\u00e9cessite une ordonnance ; l&#8217;achat sans est ill\u00e9gal (ANSM, 2023, <a href=\"https:\/\/ansm.sante.fr\/\">https:\/\/ansm.sante.fr\/<\/a>). Aux \u00c9tats-Unis, les g\u00e9n\u00e9riques comme Vidalista sont approuv\u00e9s si fabriqu\u00e9s par des laboratoires certifi\u00e9s. Dans l&#8217;UE, l&#8217;EMA r\u00e9gule les importations. Au Canada, Health Canada autorise les achats en ligne via pharmacies licenci\u00e9es (Health Canada, 2023, <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html\">https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html<\/a>). V\u00e9rifiez les lois locales pour \u00e9viter des amendes ou saisies douani\u00e8res.<\/p>\n<h3>Conseils pour v\u00e9rifier l&#8217;authenticit\u00e9<\/h3>\n<ul>\n<li>Examinez l&#8217;emballage pour hologrammes et num\u00e9ros de lot.<\/li>\n<li>Utilisez des outils comme le v\u00e9rificateur de code-barres de l&#8217;EMA.<\/li>\n<li>Contactez le fabricant (g\u00e9n\u00e9ralement Centurion Laboratories pour Vidalista) pour confirmation.<\/li>\n<li>Testez via laboratoires ind\u00e9pendants si douteux.<\/li>\n<\/ul>\n<p>Des initiatives comme l&#8217;International Medical Products Anti-Counterfeiting Taskforce (IMPACT) aident \u00e0 la v\u00e9rification (WHO, 2017, <a href=\"https:\/\/www.who.int\/initiatives\/impact\">https:\/\/www.who.int\/initiatives\/impact<\/a>).<\/p>\n<h2>Utilisation dans des populations sp\u00e9ciales<\/h2>\n<h3>Personnes \u00e2g\u00e9es<\/h3>\n<p>Chez les plus de 65 ans, une dose initiale de 5 mg est recommand\u00e9e en raison d&#8217;une clairance r\u00e9duite. Une \u00e9tude sur PubMed montre une efficacit\u00e9 similaire mais un risque accru d&#8217;effets hypotenseurs (Porst et al., 2006, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16939450\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16939450\/<\/a>).<\/p>\n<h3>Femmes enceintes et allaitantes<\/h3>\n<p>Non indiqu\u00e9 pour les femmes. Des donn\u00e9es limit\u00e9es sugg\u00e8rent aucun risque f\u0153tal, mais \u00e9vitez pendant la grossesse. L&#8217;OMS d\u00e9conseille son usage hors indications masculines (WHO, 2023).<\/p>\n<h3>Enfants<\/h3>\n<p>Contre-indiqu\u00e9 chez les mineurs ; aucune \u00e9tude p\u00e9diatrique n&#8217;existe pour la dysfonction \u00e9rectile.<\/p>\n<h2>Stockage et \u00e9limination<\/h2>\n<p>Conservez Vidalista Black \u00e0 temp\u00e9rature ambiante (15-30\u00b0C), \u00e0 l&#8217;abri de l&#8217;humidit\u00e9 et de la lumi\u00e8re. \u00c9liminez les comprim\u00e9s p\u00e9rim\u00e9s via des programmes de retour pharmaceutique pour \u00e9viter la pollution environnementale. La FDA fournit des guidelines sur la disposition s\u00e9curis\u00e9e (FDA, 2023, <a href=\"https:\/\/www.fda.gov\/consumers\/consumer-updates\/safe-disposal-medicines-unused-medicines\">https:\/\/www.fda.gov\/consumers\/consumer-updates\/safe-disposal-medicines-unused-medicines<\/a>).<\/p>\n<h2>Alternatives \u00e0 Vidalista Black<\/h2>\n<p>Outre les autres inhibiteurs de PDE5, des options incluent :<\/p>\n<ul>\n<li>Th\u00e9rapies non pharmacologiques : Pompes \u00e0 vide, implants p\u00e9niens.<\/li>\n<li>Traitements sous-jacents : Gestion du diab\u00e8te ou de l&#8217;hypertension.<\/li>\n<li>M\u00e9dicaments naturels : L-arginine, mais avec efficacit\u00e9 variable (non approuv\u00e9e par FDA).<\/li>\n<\/ul>\n<p>Une revue Cochrane \u00e9value ces alternatives, soulignant la sup\u00e9riorit\u00e9 des PDE5 pour l&#8217;efficacit\u00e9 prouv\u00e9e (Hatzimouratidis et al., 2019, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30873507\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30873507\/<\/a>).<\/p>\n<h2>Approbations r\u00e9glementaires<\/h2>\n<p>Vidalista Black, en tant que g\u00e9n\u00e9rique, n&#8217;est pas directement approuv\u00e9 par la FDA, mais le tadalafil l&#8217;est depuis 2003. En Inde, o\u00f9 il est produit, il respecte les normes CDSCO. L&#8217;EMA approuve les \u00e9quivalents g\u00e9n\u00e9riques. V\u00e9rifiez les approbations locales pour la l\u00e9galit\u00e9 (CDSCO, 2023, <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/\">https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/<\/a>).<\/p>\n<h2>R\u00e9f\u00e9rences<\/h2>\n<ol>\n<li>McMahon, C. G., et al. (2006). Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. <em>Journal of Sexual Medicine<\/em>, 3(4), 688-695. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16422974\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16422974\/<\/a><\/li>\n<li>WHO. (2023). Sexual health. <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexual-health\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexual-health<\/a><\/li>\n<li>Hatzimouratidis, K., et al. (2010). Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. <em>European Urology<\/em>, 57(5), 804-814. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20141500\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20141500\/<\/a><\/li>\n<li>Brock, G. B., et al. (2002). Tadalafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <em>Clinical Cornerstone<\/em>, 4(4), 45-55. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12041983\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/12041983\/<\/a><\/li>\n<li>EMA. (2023). Cialis. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis<\/a><\/li>\n<li>Eardley, I., et al. (2010). Drugs for treatment of erectile dysfunction: an overview. <em>BJU International<\/em>, 105(1), 4-9. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19930456\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/19930456\/<\/a><\/li>\n<li>FDA. (2023). Cialis Label. <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021368s020s021lbl.pdf\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021368s020s021lbl.pdf<\/a><\/li>\n<li>Kloner, R. A., et al. (2004). Cardiovascular safety of phosphodiesterase-5 inhibitors. <em>Circulation<\/em>, 109(14), 1747-1753. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15036680\/<\/a><\/li>\n<li>EMA. (2023). Cialis Product Information. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis#product-information-section\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cialis#product-information-section<\/a><\/li>\n<li>Kloner, R. A. (2004). Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <em>Circulation<\/em>, 110(19), e380-e385. <a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.0000146906.42375.D4\">https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.0000146906.42375.D4<\/a><\/li>\n<li>EMA. (2023). Cialis EPAR Product Information (French). <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_fr.pdf\">https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_fr.pdf<\/a><\/li>\n<li>Montorsi, F., et al. (2004). Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. <em>European Urology<\/em>, 45(3), 339-345. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15036699\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/15036699\/<\/a><\/li>\n<li>Statista. (2023). Online Pharmacies. <a href=\"https:\/\/www.statista.com\/topics\/1764\/online-pharmacies\/\">https:\/\/www.statista.com\/topics\/1764\/online-pharmacies\/<\/a><\/li>\n<li>WHO. (2022). Global health product supply chains. <a href=\"https:\/\/www.who.int\/news\/item\/17-05-2022-who-warns-of-prolonged-consequences-of-covid-19-for-global-health-product-supply-chains\">https:\/\/www.who.int\/news\/item\/17-05-2022-who-warns-of-prolonged-consequences-of-covid-19-for-global-health-product-supply-chains<\/a><\/li>\n<li>FDA. (2023). Counterfeit Medicine. <a href=\"https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine\">https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/counterfeit-medicine<\/a><\/li>\n<li>ANSM. (2023). Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament. <a href=\"https:\/\/ansm.sante.fr\/\">https:\/\/ansm.sante.fr\/<\/a><\/li>\n<li>Health Canada. (2023). Internet Pharmacy. <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html\">https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/internet-pharmacy.html<\/a><\/li>\n<li>WHO. (2017). IMPACT. <a href=\"https:\/\/www.who.int\/initiatives\/impact\">https:\/\/www.who.int\/initiatives\/impact<\/a><\/li>\n<li>Porst, H., et al. (2006). The efficacy and safety of tadalafil administered once a day for the treatment of erectile dysfunction. <em>BJU International<\/em>, 98(5), 1003-1009. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16939450\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16939450\/<\/a><\/li>\n<li>FDA. (2023). Safe Disposal of Medicines. <a href=\"https:\/\/www.fda.gov\/consumers\/consumer-updates\/safe-disposal-medicines-unused-medicines\">https:\/\/www.fda.gov\/consumers\/consumer-updates\/safe-disposal-medicines-unused-medicines<\/a><\/li>\n<li>Hatzimouratidis, K., et al. (2019). Contemporary Update of the European Association of Urology Guidelines on Male Sexual Dysfunction. <em>European Urology<\/em>, 76(1), 81-90. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30873507\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30873507\/<\/a><\/li>\n<li>CDSCO. (2023). Central Drugs Standard Control Organization. <a href=\"https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/\">https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/<\/a><\/li>\n<\/ol>\n<p><\/body><br \/>\n<\/html><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vidalista Black est un m\u00e9dicament g\u00e9n\u00e9rique contenant du tadalafil, principalement utilis\u00e9 pour traiter la dysfonction \u00e9rectile chez les hommes. Ce principe actif, similaire \u00e0 celui du Cialis de marque, agit en inhibant l&#8217;enzyme phosphodiest\u00e9rase de type 5 (PDE5), favorisant ainsi une meilleure circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle. Selon une \u00e9tude publi\u00e9e [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":544,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dysfonction-erectile"],"yoast_head":"\n<title>Vidalista Black : Un aper\u00e7u complet du m\u00e9dicament<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vidalista Black : Un aper\u00e7u complet du m\u00e9dicament\" \/>\n<meta property=\"og:description\" content=\"Vidalista Black est un m\u00e9dicament g\u00e9n\u00e9rique contenant du tadalafil, principalement utilis\u00e9 pour traiter la dysfonction \u00e9rectile chez les hommes. Ce principe actif, similaire \u00e0 celui du Cialis de marque, agit en inhibant l&#8217;enzyme phosphodiest\u00e9rase de type 5 (PDE5), favorisant ainsi une meilleure circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle. Selon une \u00e9tude publi\u00e9e [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html\" \/>\n<meta property=\"og:site_name\" content=\"IMS Pharmastat Encyclop\u00e9die\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T00:25:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T00:25:32+00:00\" \/>\n<meta name=\"author\" content=\"Mathieu-D&#039;Argent\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mathieu-D&#039;Argent\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html\"},\"author\":{\"name\":\"Mathieu-D'Argent\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"headline\":\"Vidalista Black\",\"datePublished\":\"2026-02-04T00:25:30+00:00\",\"dateModified\":\"2026-02-04T00:25:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html\"},\"wordCount\":1915,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Vidalista-Black.webp\",\"articleSection\":[\"Dysfonction \u00e9rectile\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html\",\"name\":\"Vidalista Black : Un aper\u00e7u complet du m\u00e9dicament\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Vidalista-Black.webp\",\"datePublished\":\"2026-02-04T00:25:30+00:00\",\"dateModified\":\"2026-02-04T00:25:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#primaryimage\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Vidalista-Black.webp\",\"contentUrl\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Vidalista-Black.webp\",\"width\":720,\"height\":810,\"caption\":\"Vidalista Black\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/dysfonction-erectile\\\/vidalista-black.html#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vidalista Black\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#website\",\"url\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/\",\"name\":\"IMS Pharmastat Encyclop\u00e9die\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\\\/#\\\/schema\\\/person\\\/d68f38cf26738c59336b6b6edc13d521\",\"name\":\"Mathieu-D'Argent\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g\",\"caption\":\"Mathieu-D'Argent\"},\"sameAs\":[\"https:\\\/\\\/www.ims-pharmastat.fr\\\/encyclopedie\"]}]}<\/script>\n","yoast_head_json":{"title":"Vidalista Black : Un aper\u00e7u complet du m\u00e9dicament","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html","og_locale":"fr_FR","og_type":"article","og_title":"Vidalista Black : Un aper\u00e7u complet du m\u00e9dicament","og_description":"Vidalista Black est un m\u00e9dicament g\u00e9n\u00e9rique contenant du tadalafil, principalement utilis\u00e9 pour traiter la dysfonction \u00e9rectile chez les hommes. Ce principe actif, similaire \u00e0 celui du Cialis de marque, agit en inhibant l&#8217;enzyme phosphodiest\u00e9rase de type 5 (PDE5), favorisant ainsi une meilleure circulation sanguine vers le p\u00e9nis lors d&#8217;une stimulation sexuelle. Selon une \u00e9tude publi\u00e9e [&hellip;]","og_url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html","og_site_name":"IMS Pharmastat Encyclop\u00e9die","article_published_time":"2026-02-04T00:25:30+00:00","article_modified_time":"2026-02-04T00:25:32+00:00","author":"Mathieu-D'Argent","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Mathieu-D'Argent","Dur\u00e9e de lecture estim\u00e9e":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#article","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html"},"author":{"name":"Mathieu-D'Argent","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"headline":"Vidalista Black","datePublished":"2026-02-04T00:25:30+00:00","dateModified":"2026-02-04T00:25:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html"},"wordCount":1915,"commentCount":0,"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Vidalista-Black.webp","articleSection":["Dysfonction \u00e9rectile"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html","name":"Vidalista Black : Un aper\u00e7u complet du m\u00e9dicament","isPartOf":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#primaryimage"},"image":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#primaryimage"},"thumbnailUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Vidalista-Black.webp","datePublished":"2026-02-04T00:25:30+00:00","dateModified":"2026-02-04T00:25:32+00:00","author":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521"},"breadcrumb":{"@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#primaryimage","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Vidalista-Black.webp","contentUrl":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/petri\/2026\/02\/Vidalista-Black.webp","width":720,"height":810,"caption":"Vidalista Black"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/dysfonction-erectile\/vidalista-black.html#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/"},{"@type":"ListItem","position":2,"name":"Vidalista Black"}]},{"@type":"WebSite","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#website","url":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/","name":"IMS Pharmastat Encyclop\u00e9die","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/#\/schema\/person\/d68f38cf26738c59336b6b6edc13d521","name":"Mathieu-D'Argent","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5b3cef651a7872eb22dc19b65cd9e7a356b001699c811a68020f23d0bf86837f?s=96&d=mm&r=g","caption":"Mathieu-D'Argent"},"sameAs":["https:\/\/www.ims-pharmastat.fr\/encyclopedie"]}]}},"_links":{"self":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/comments?post=148"}],"version-history":[{"count":1,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/148\/revisions"}],"predecessor-version":[{"id":149,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/posts\/148\/revisions\/149"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media\/544"}],"wp:attachment":[{"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/media?parent=148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/categories?post=148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ims-pharmastat.fr\/encyclopedie\/wp-json\/wp\/v2\/tags?post=148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}